Literature DB >> 11081782

Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group.

L H Lindholm1, L Hansson, T Ekbom, B Dahlöf, J Lanke, E Linjer, B Scherstén, P O Wester, T Hedner, U de Faire.   

Abstract

BACKGROUND: The benefits of treating hypertension in elderly diabetic patients, in terms of achieving reductions in cardiovascular morbidity and mortality, have been documented in several recent prospective trials. There has, however, been some controversy regarding the effect of different antihypertensive drugs on the frequency of myocardial infarction in this group of patients.
DESIGN: STOP Hypertension-2 was a prospective, randomized, open trial with blinded endpoint evaluation.
METHODS: We studied 6614 elderly patients aged 70-84 years; 719 of them had diabetes mellitus at the start of the study (mean age 75.8 years). Patients were randomly assigned to one of three treatment strategies: conventional antihypertensive drugs (diuretics or beta-blockers), calcium antagonists, or angiotensin converting enzyme (ACE) inhibitors.
RESULTS: Reduction in blood pressure was similar in the three treatment groups of diabetics. The prevention of cardiovascular mortality was also similar; the frequency of this primary endpoint did not differ significantly between the three groups. There were, however, significantly fewer (P = 0.025) myocardial infarctions during ACE inhibitor treatment (n = 17) than during calcium antagonist treatment (n = 32; relative risk 0.51, 95% confidence interval 0.28-0.92); but a (non-significant) tendency to more strokes during ACE inhibitor treatment (n = 34 compared with n = 29; relative risk 1.16, 95% confidence interval 0.71-1.91).
CONCLUSION: Treatment of hypertensive diabetic patients with conventional antihypertensive drugs (diuretics, beta-blockers, or both) seemed to be as effective as treatment with newer drugs such as calcium antagonists or ACE inhibitors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11081782     DOI: 10.1097/00004872-200018110-00020

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  27 in total

Review 1.  Treatment of coexisting diabetes and hypertension.

Authors:  N M Kaplan
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

Review 2.  Best strategies for hypertension management in type 2 diabetes and obesity.

Authors:  Darren M Allcock; James R Sowers
Journal:  Curr Diab Rep       Date:  2010-04       Impact factor: 4.810

Review 3.  Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.

Authors:  Christine R Culy; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Diabetes: treating hypertension.

Authors:  Sandeep Vijan
Journal:  BMJ Clin Evid       Date:  2009-11-09

Review 5.  Japanese Clinical Practice Guideline for Diabetes 2019.

Authors:  Eiichi Araki; Atsushi Goto; Tatsuya Kondo; Mitsuhiko Noda; Hiroshi Noto; Hideki Origasa; Haruhiko Osawa; Akihiko Taguchi; Yukio Tanizawa; Kazuyuki Tobe; Narihito Yoshioka
Journal:  Diabetol Int       Date:  2020-07-24

Review 6.  Type 2 Diabetes and Thiazide Diuretics.

Authors:  André J Scheen
Journal:  Curr Diab Rep       Date:  2018-02-05       Impact factor: 4.810

Review 7.  Lessons from trials in hypertensive type 2 diabetic patients.

Authors:  Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

Review 8.  Understanding the quality chasm for hypertension control in diabetes: a structured review of "co-maneuvers" used in clinical trials.

Authors:  Aanand D Naik; Tim T Issac; Richard L Street; Mark E Kunik
Journal:  J Am Board Fam Med       Date:  2007 Sep-Oct       Impact factor: 2.657

Review 9.  Are low target blood pressure goals justified in persons with diabetes mellitus?

Authors:  Errol D Crook; Latha Velusamy
Journal:  Curr Hypertens Rep       Date:  2003-06       Impact factor: 5.369

Review 10.  The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications.

Authors:  Toomas Podar; Jaakko Tuomilehto
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.